Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with That of Heart Failure

Circulation

Volumn 136, Issue 16, 2017, Pages 1548-1559

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

diabetes; heart failure; sodium hydrogen exchanger

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; MINERALOCORTICOID ANTAGONIST; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; SODIUM PROTON EXCHANGE PROTEIN 3; CARDIOVASCULAR AGENT; CATION TRANSPORT PROTEIN; SLC9A1 PROTEIN, HUMAN; SODIUM-HYDROGEN EXCHANGER 3;

CARDIAC MUSCLE CELL; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLYCATION; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; COMORBIDITY; DISEASE COURSE; DRUG INTERACTION; METABOLISM; POLYPHARMACY; RISK FACTOR;

ANIMALS; CARDIOVASCULAR AGENTS; CATION TRANSPORT PROTEINS; COMORBIDITY; DIABETES MELLITUS; DISEASE PROGRESSION; DRUG INTERACTIONS; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; POLYPHARMACY; RISK FACTORS; SODIUM-HYDROGEN ANTIPORTER;

EID: 85031915334     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.030418     Document Type: Review

References (198)

1. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D, Krum H, McMurray JJ. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J. 2008;29:1224-1240. doi: 10.1093/eurheartj/ehn156.
2. Ciccone MM, Iacoviello M, Puzzovivo A, Scicchitano P, Monitillo F, De Crescenzo F, Caragnano V, Sassara M, Quistelli G, Guida P, Favale S. Clinical correlates of endothelial function in chronic heart failure. Clin Res Cardiol. 2011;100:515-521. doi: 10.1007/s00392-010-0275-y.
3. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Rydén L. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005;28:612-616. doi: 10.2337/diacare.28.3612.
4. Nielson C, Lange T. Blood glucose and heart failure in nondiabetic patients. Diabetes Care. 2005;28:607-611. doi: 10.2337/diacare.28.3.607.
5. Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K; ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007;115:1371-1375. doi: 10.1161/CIRCULATIONAHA. 106.661405.
6. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM- HF Investigators and Committees. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016;9:pii:e002560. doi: 10.1161/CIRCHEARTFAILURE. 115.002560.
7. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S; CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008;168:1699-1704. doi: 10.1001/archinte.168.15.1699.
8. Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A. Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J Am Coll Cardiol. 2016;68:1404-1416. doi: 10.1016/j.jacc.2016.06.061.
9. Guglin M, Villafranca A, Morrison A. Cardiogenic diabetes. Heart Fail Rev. 2014;19:595-602. doi: 10.1007/s10741-013-9412-9.
10. Uriel N, Naka Y, Colombo PC, Farr M, Pak SW, Cotarlan V, Albu JB, Gallagher D, Mancini D, Ginsberg HN, Jorde UP. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail. 2011;13:195-199. doi: 10.1093/eurjhf/hfq204.
11. Selvin E, Lazo M, Chen Y, Shen L, Rubin J, McEvoy JW, Hoogeveen RC, Sharrett AR, Ballantyne CM, Coresh J. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014;130:1374- 1382. doi: 10.1161/CIRCULATIONAHA.114.010815.
12. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 1991;260(5 Pt 2):H1406-H1414.
13. Neuringer JR, Brenner BM. Glomerular hypertension: cause and consequence of renal injury. J Hypertens Suppl. 1992;10:S91-S97.
14. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl. 2005;23:S9-S17.
15. Falskov B, Hermann TS, Rask-Madsen C, Major-Pedersen A, Christiansen B, Raunsø J, Køber L, Torp-Pedersen C, Dominguez H. The effect of chronic heart failure and type 2 diabetes on insulin-stimulated endothelial function is similar and additive. Vasc Health Risk Manag. 2011;7:771-776. doi: 10.2147/VHRM.S25724.
16. Scherbakov N, Bauer M, Sandek A, Szabó T, Töpper A, Jankowska EA, Springer J, von Haehling S, Anker SD, Lainscak M, Engeli S, Düngen HD, Doehner W. Insulin resistance in heart failure: differences between patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2015;17:1015-1021. doi: 10.1002/ejhf.317.
17. AlZadjali MA, Godfrey V, Khan F, Choy A, Doney AS, Wong AK, Petrie JR, Struthers AD, Lang CC. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol. 2009;53:747-753. doi: 10.1016/j. jacc.2008.08.081.
18. Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B, Reusch JE, Regensteiner JG. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab. 2009;94:3687-3695. doi: 10.1210/jc.2008-2844.
19. Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA. Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial. J Clin Endocrinol Metab. 2000;85:2463-2468. doi: 10.1210/jcem.85.7.6692.
20. Kemppainen J, Tsuchida H, Stolen K, Karlsson H, Björnholm M, Heinonen OJ, Nuutila P, Krook A, Knuuti J, Zierath JR. Insulin signalling and resistance in patients with chronic heart failure. J Physiol. 2003;550(Pt 1):305-315. doi: 10.1113/jphysiol.2003.042648.
21. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, Petrie JR, Struthers AD, Lang CC. The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail. 2012;14:1303-1310. doi: 10.1093/eurjhf/hfs106.
22. Doehner W, Todorovic J, Kennecke C, Rauchhaus M, Sandek A, Lainscak M, van Linthout S, Tschöpe C, von Haehling S, Anker SD. Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo- controlled study. Int J Cardiol. 2012;161:137-142. doi: 10.1016/j.ijcard. 2011.07.051.
23. Mishima T, Tanimura M, Suzuki G, Todor A, Sharov VG, Tanhehco EJ, Goldstein S, Sabbah HN. Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure. Cardiovasc Drugs Ther. 2002;16:209-214.
24. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254. doi: 10.1016/0735-1097(92)90167-L.
25. Bayés-Genís A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, Urrutia A, Lupón J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65:657-665. doi: 10.1016/j.jacc.2014.11.048.
26. Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM, Grant PJ. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond). 2011;35:1031-1040. doi: 10.1038/ ijo.2010.227.
27. Yorek MS, Obrosov A, Lu B, Gerard C, Kardon RH, Yorek MA. Effect of inhibition or deletion of neutral endopeptidase on neuropathic endpoints in high fat fed/low dose streptozotocin-treated mice [published online ahead of print September 15, 2016]. J Neuropathol Exp Neurol. doi: 10.1093/ jnen/nlw083.
28. Takata H, Takeda Y, Zhu A, Cheng Y, Yoneda T, Demura M, Yagi K, Karashima S, Yamagishi M. Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats. Diabetes Obes Metab. 2012;14:155-162. doi: 10.1111/j.1463-1326.2011.01499.x.
29. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res. 2009;104:124-133. doi: 10.1161/CIRCRESAHA.108.176008.
30. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care. 2016;39:1115-1122. doi: 10.2337/ dc16-0542.
31. Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol. 2014;64:1388-1400. doi: 10.1016/j.jacc.2014.04.083.
32. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, McMurray JJ. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J. 2007;28:829-835. doi: 10.1093/ eurheartj/ehm033.
33. Faxén UL, Hage C, Andreasson A, Donal E, Daubert JC, Linde C, Brismar K, Lund LH. HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. Int J Cardiol. 2017;228:709-716. doi: 10.1016/j. ijcard.2016.11.194.
34. Atluri P, Morine KJ, Liao GP, Panlilio CM, Berry MF, Hsu VM, Hiesinger W, Cohen JE, Joseph Woo Y. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett. 2007;12:127-138. doi: 10.2478/s11658-006-0058-7.
35. Karmazyn M, Gan XT, Rajapurohitam V. The potential contribution of circulating and locally produced leptin to cardiac hypertrophy and failure. Can J Physiol Pharmacol. 2013;91:883-888. doi: 10.1139/cjpp-2013- 0057.
36. Wang Y, Ma XL, Lau WB. Cardiovascular adiponectin resistance: the critical role of adiponectin receptor modification. Trends Endocrinol Metab. 2017;28:519-530. doi: 10.1016/j.tem.2017.03.004.
37. Baldasseroni S, Antenore A, Di Serio C, Orso F, Lonetto G, Bartoli N, Foschini A, Marella A, Pratesi A, Scarantino S, Fumagalli S, Monami M, Mannucci E, Marchionni N, Tarantini F. Adiponectin, diabetes and ischemic heart failure: a challenging relationship. Cardiovasc Diabetol. 2012;11:151. doi: 10.1186/1475-2840-11-151.
38. Dunmore SJ, Brown JE. The role of adipokines in β-cell failure of type 2 diabetes. J Endocrinol. 2013;216:T37-T45. doi: 10.1530/JOE-12-0278.
39. Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, Kelly ME, Chatterjee Bhowmick D, Murano I, Cohen P, Banks AS, Khandekar MJ, Dietrich A, Flier JS, Cinti S, Blüher M, Danial NN, Berggren PO, Spiegelman BM. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158:41-53. doi: 10.1016/j.cell.2014.06.005.
40. Frühbeck G. The adipose tissue as a source of vasoactive factors. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:197-208. doi: 10.2174/1568016043356255.
41. Essick EE, Wilson RM, Pimentel DR, Shimano M, Baid S, Ouchi N, Sam F. Adiponectin modulates oxidative stress-induced autophagy in cardiomyocytes. PLoS One. 2013;8:e68697. doi: 10.1371/journal. pone.0068697.
42. O'Shea KM, Chess DJ, Khairallah RJ, Rastogi S, Hecker PA, Sabbah HN, Walsh K, Stanley WC. Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload. Am J Physiol Heart Circ Physiol. 2010;298:H1639-H1645. doi: 10.1152/ajpheart. 00957.2009.
43. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74:11-18. doi: 10.1016/j.cardiores. 2006.10.009.
44. Zhong JC, Zhang ZZ, Wang W, McKinnie SMK, Vederas JC, Oudit GY. Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases. Biochim Biophys Acta. 2017;1863:1942-1950. doi: 10.1016/j.bbadis.2016.11.007.
45. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori M, Matsuzawa Y, Funahashi T, Kitakaze M. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res. 2005;67:705-713. doi: 10.1016/j. cardiores.2005.04.018.
46. Alfarano C, Foussal C, Lairez O, Calise D, Attané C, Anesia R, Daviaud D, Wanecq E, Parini A, Valet P, Kunduzova O. Transition from metabolic adaptation to maladaptation of the heart in obesity: role of apelin. Int J Obes (Lond). 2015;39:312-320. doi: 10.1038/ijo.2014.122.
47. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Papacosta O, Sattar N. The obesity paradox in men with coronary heart disease and heart failure: the role of muscle mass and leptin. Int J Cardiol. 2014;171:49-55. doi: 10.1016/j.ijcard.2013.11.043.
48. Czarzasta K, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Fus L, Puchalska L, Gondek A, Dobruch J, Gomolka R, Wrzesien R, Zera T, Gornicka B, Kuch M. The role of apelin in central cardiovascular regulation in rats with post-infarct heart failure maintained on a normal fat or high fat diet. Clin Exp Pharmacol Physiol. 2016;43:983-994. doi: 10.1111/1440-1681.12617.
49. Booth A, Magnuson A, Fouts J, Foster MT. Adipose tissue: an endocrine organ playing a role in metabolic regulation. Horm Mol Biol Clin Investig. 2016;26:25-42. doi: 10.1515/hmbci-2015-0073.
50. Tanaka K, Wilson RM, Essick EE, Duffen JL, Scherer PE, Ouchi N, Sam F. Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:976-985. doi: 10.1161/CIRCHEARTFAILURE.114.001279.
51. Gunawardana SC. Benefits of healthy adipose tissue in the treatment of diabetes. World J Diabetes. 2014;5:420-430. doi: 10.4239/wjd.v5.i4.420.
52. Jung CH, Kim BY, Mok JO, Kang SK, Kim CH. Association between serum adipocytokine levels and microangiopathies in patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5:333-339. doi: 10.1111/jdi.12144.
53. Araújo JP, Lourenço P, Rocha-Gonçalves F, Ferreira A, Bettencourt P. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail. 2009;11:567-572. doi: 10.1093/eurjhf/hfp046.
54. Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, Flyvbjerg A, Faber J. Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study. Metabolism. 2014;63:141-149. doi: 10.1016/j.metabol.2013.09.017.
55. Roul D, Recchia FA. Metabolic alterations induce oxidative stress in diabetic and failing hearts: different pathways, same outcome. Antioxid Redox Signal. 2015;22:1502-1514. doi: 10.1089/ars.2015.6311.
56. Hartupee J, Mann DL. Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res. 2013;6:485-492. doi: 10.1007/ s12265-013-9467-y.
57. Nguyen DV, Shaw LC, Grant MB. Inflammation in the pathogenesis of microvascular complications in diabetes. Front Endocrinol (Lausanne). 2012;3:170. doi: 10.3389/fendo.2012.00170.
58. Rojas A, Mercadal E, Figueroa H, Morales MA. Advanced glycation and ROS: a link between diabetes and heart failure. Curr Vasc Pharmacol. 2008;6:44-51. doi: 10.2174/157016108783331312.
59. Nozyński J, Zakliczyński M, Konecka-Mrowka D, Zielinska T, Zakliczynska H, Nikiel B, Mlynarczyk-Liszka J, Mrowka A, Zembala-Nozynska E, Pijet M, Rdzanowska K, Lange D, Przybylski R, Zembala M. Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann Transplant. 2012;17:53-61. doi: 10.12659/AOT.883223.
60. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive Investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30:2773-2778. doi: 10.2337/dc07-0717.
61. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326. doi: 10.1056/NEJMoa1307684.
62. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.
63. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes [published online ahead of print June 12, 2017]. N Engl J Med. doi: 10.1056/NEJMoa1611925.
64. Yang Y, Wei RB, Wang ZC, Wang N, Gao YW, Li MX, Qiu Q. A meta-analysis of the effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on insulin sensitivity in hypertensive patients without diabetes. Diabetes Res Clin Pract. 2015;107:415-23. doi: 10.1016/j.diabres. 2014.11.007.
65. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5:333-340. doi: 10.1016/S2213-8587(17)30087-6.
66. Polyzos SA, Kountouras J, Mantzoros CS, Polymerou V, Katsinelos P. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial [published online ahead of print April 28, 2017]. Diabetes Obes Metab. doi: 10.1111/dom.12989.
67. Packer M, Anker S, Butler J, Filippatos G, Zannad F. Effects of sodiumglucose cotransporter 2 for the treatment of patients with heart failure: proposal of a novel mechanism of action [published online ahead of print August 2, 2017]. JAMA Cardiol. doi: 10.1001/jamacardio.2017.2275.
68. Orlowski J, Grinstein S. Na+/H+ exchangers. Compr Physiol. 2011;1:2083- 2100. doi: 10.1002/cphy.c110020.
69. Padan E, Landau M. Sodium-proton (Na(+)/H(+)) antiporters: properties and roles in health and disease. Met Ions Life Sci. 2016;16:391-458. doi: 10.1007/978-3-319-21756-7-12.
70. Odunewu-Aderibigbe A, Fliegel L. The Na(+) /H(+) exchanger and pH regulation in the heart. IUBMB Life. 2014;66:679-685. doi: 10.1002/iub.1323.
71. + exchanger. J Mol Cell Cardiol. 2013;61:60-67. doi: 10.1016/j. yjmcc.2012.11.019.
72. Girardi AC, Di Sole F. Deciphering the mechanisms of the Na+/H+ exchanger- 3 regulation in organ dysfunction. Am J Physiol Cell Physiol. 2012;302:C1569-C1587. doi: 10.1152/ajpcell.00017.2012.
73. Donowitz M, Mohan S, Zhu CX, Chen TE, Lin R, Cha B, Zachos NC, Murtazina R, Sarker R, Li X. NHE3 regulatory complexes. J Exp Biol. 2009;212(Pt 11):1638-1646. doi: 10.1242/jeb.028605.
74. Karmazyn M, Liu Q, Gan XT, Brix BJ, Fliegel L. Aldosterone increases NHE-1 expression and induces NHE-1-dependent hypertrophy in neonatal rat ventricular myocytes. Hypertension. 2003;42:1171-1176. doi: 10.1161/01.HYP.0000102863.23854.0B.
75. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury. Hypertension. 2003;41:493-498. doi: 10.1161/01. HYP.0000056769.73726.E5.
76. Inoue BH, dos Santos L, Pessoa TD, Antonio EL, Pacheco BP, Savignano FA, Carraro-Lacroix LR, Tucci PJ, Malnic G, Girardi AC. Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. Am J Physiol Regul Integr Comp Physiol. 2012;302:R166-R174. doi: 10.1152/ajpregu.00127.2011.
77. Lütken SC, Kim SW, Jonassen T, Marples D, Knepper MA, Kwon TH, Frøkiaer J, Nielsen S. Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade. Am J Physiol Renal Physiol. 2009;297:F1678-F1688. doi: 10.1152/ ajprenal.00010.2009.
78. Ambühl P, Amemiya M, Preisig PA, Moe OW, Alpern RJ. Chronic hyperosmolality increases NHE3 activity in OKP cells. J Clin Invest. 1998;101:170-177. doi: 10.1172/JCI62.
79. Ganz MB, Hawkins K, Reilly RF. High glucose induces the activity and expression of Na(+)/H(+) exchange in glomerular mesangial cells. Am J Physiol Renal Physiol. 2000;278:F91-F96.
80. Leineweber K, Heusch G, Schulz R. Regulation and role of the presynaptic and myocardial Na+/H+ exchanger NHE1: effects on the sympathetic nervous system in heart failure. Cardiovasc Drug Rev. 2007;25:123-131. doi: 10.1111/j.1527-3466.2007.00010.x.
81. Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res. 2008;103:891-899. doi: 10.1161/CIRCRESAHA.108.175141.
82. Fuster DG, Bobulescu IA, Zhang J, Wade J, Moe OW. Characterization of the regulation of renal Na+/H+ exchanger NHE3 by insulin. Am J Physiol Renal Physiol. 2007;292:F577-F585. doi: 10.1152/ajprenal.00240.2006.
83. Yang LE, Leong PK, Ye S, Campese VM, McDonough AA. Responses of proximal tubule sodium transporters to acute injury-induced hypertension. Am J Physiol Renal Physiol. 2003;284:F313-F322. doi: 10.1152/ ajprenal.00134.2002.
84. Lawrence SP, Holman GD, Koumanov F. Translocation of the Na+/H+ exchanger 1 (NHE1) in cardiomyocyte responses to insulin and energy-status signalling. Biochem J. 2010;432:515-523. doi: 10.1042/BJ20100717.
85. Xiao XH, Allen DG. The role of endogenous angiotensin II in ischaemia, reperfusion and preconditioning of the isolated rat heart. Pflugers Arch. 2003;445:643-650. doi: 10.1007/s00424-002-0990-y.
86. Tepel M, van der Giet M, Brukamp K, Weyer J, Zidek W. Regulation of the Na+/H+ antiporter in patients with mild chronic renal failure: effect of glucose. Kidney Int. 1999;56:172-180. doi: 10.1046/j.1523-1755.1999.00510.x.
87. Carreño JE, Verdugo FJ, Contreras F, Montellano FA, Veloso S, Schalper KA, Sandoval M, Villanueva S, Marusic E, Irarrazabal CE. Spironolactone inhibits the activity of the Na+/H+ exchanger in the aorta of mineralocorticoid- induced hypertensive rats. J Renin Angiotensin Aldosterone Syst. 2015;16:1225-1231. doi: 10.1177/1470320315587193.
88. Vial G, Dubouchaud H, Couturier K, Lanson M, Leverve X, Demaison L. Na+/H+ exchange inhibition with cariporide prevents alterations of coronary endothelial function in streptozotocin-induced diabetes. Mol Cell Biochem. 2008;310:93-102. doi: 10.1007/s11010-007-9669-1.
89. LaPointe MS, Batlle DC. Na+/H+ exchange and vascular smooth muscle proliferation. Am J Med. Sci. 1994;307(Suppl 1):S9-S16.
90. Kahn AM, Yang M. Insulin increases acid production and may directly stimulate Na/H(+) exchange activity in cultured vascular smooth muscle cells. J Vasc Res. 2011;48:505-512. doi: 10.1159/000329587.
91. Jandeleit-Dahm K, Hannan KM, Farrelly CA, Allen TJ, Rumble JR, Gilbert RE, Cooper ME, Little PJ. Diabetes-induced vascular hypertrophy is accompanied by activation of Na(+)-H(+) exchange and prevented by Na(+)-H(+) exchange inhibition. Circ Res. 2000;87:1133-1140. doi: 10.1161/01.RES.87.12.1133.
92. Pickkers P, van Beek M, Hughes AD, Russel FG, Thien T, Smits P. Presence and mechanism of direct vascular effects of amiloride in humans. J Cardiovasc Pharmacol. 1999;34:388-393.
93. Konstantinou-Tegou A, Kaloyianni M, Bourikas D, Koliakos G. The effect of leptin on Na(+)-H(+) antiport (NHE 1) activity of obese and normal subjects erythrocytes. Mol Cell Endocrinol. 2001;183:11-18. doi: 10.1016/ S0303-7207(01)00639-6.
94. Sarigianni M, Tsapas A, Mikhailidis DP, Kaloyianni M, Koliakos G, Paletas K. Involvement of signaling molecules on na/h exchanger-1 activity in human monocytes. Open Cardiovasc Med J. 2010;4:181-188. doi: 10.2174/1874192401004010181.
95. Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, Toya Y, Fukamizu A, Kitamura H, Umemura S. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2006;26:1267-1272. doi: 10.1161/01.ATV.0000218841.39828.91.
96. Yokoyama H, Gunasegaram S, Harding SE, Avkiran M. Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium. J Am Coll Cardiol. 2000;36:534-540. doi: 10.1016/S0735-1097(00)00730-0.
97. Hui Y, Junzhu C, Jianhua Z. Gap junction and Na+-H+ exchanger alternations in fibrillating and failing atrium. Int J Cardiol. 2008;128:147-149. doi: 10.1016/j.ijcard.2007.06.070.
98. + transport in the normal and failing heart: remember the balance. J Mol Cell Cardiol. 2013;61:2-10. doi: 10.1016/j. yjmcc.2013.04.011.
99. Baartscheer A, Schumacher CA, van Borren MM, Belterman CN, Coronel R, Fiolet JW. Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res. 2003;57:1015-1024.
100. Baartscheer A, Schumacher CA, van Borren MM, Belterman CN, Coronel R, Opthof T, Fiolet JW. Chronic inhibition of Na+/H+-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res. 2005;65:83-92. doi: 10.1016/j.cardiores.2004.09.024.
101. Kilić A, Huang CX, Rajapurohitam V, Madwed JB, Karmazyn M. Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation. J Pharmacol Exp Ther. 2014;351:492-499. doi: 10.1124/ jpet.114.217091.
102. Aker S, Snabaitis AK, Konietzka I, Van De Sand A, Böngler K, Avkiran M, Heusch G, Schulz R. Inhibition of the Na+/H+ exchanger attenuates the deterioration of ventricular function during pacing-induced heart failure in rabbits. Cardiovasc Res. 2004;63:273-282. doi: 10.1016/j. cardiores.2004.04.014.
103. Engelhardt S, Hein L, Keller U, Klämbt K, Lohse MJ. Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res. 2002;90:814-819. doi: 10.1161/01.RES.0000014966.97486.C0.
104. Kusumoto K, Haist JV, Karmazyn M. Na(+)/H(+) exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am J Physiol Heart Circ Physiol. 2001;280:H738-H745.
105. Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, Jessel A, Kereiakes D, Knight J, Thulin L, Theroux P; GUARD During Ischemia Against Necrosis (GUARDIAN) Study Investigators. Impact of sodiumhydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg. 2003;126:420-427. doi: 10.1016/S0022-5223(03)00209-5.
106. Mentzer RM Jr, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, Haverich A, Knight J, Menasché P, Myers ML, Nicolau J, Simoons M, Thulin L, Weisel RD; EXPEDITION Study Investigators. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg. 2008;85:1261-1270. doi: 10.1016/j.athoracsur.2007.10.054.
107. Russell JC, Proctor SD, Kelly SE, Löhn M, Busch AE, Schäfer S. Insulinsensitizing and cardiovascular effects of the sodium-hydrogen exchange inhibitor, cariporide, in the JCR: LA-cp rat and db/db mouse. J Cardiovasc Pharmacol. 2005;46:746-753.
108. Wu S, Yang Q, Liu Q, Song T, Zhou S, Liu Y, Liu L. Cariporide, a specific Na/H(+) exchanger 1 blocker, inhibits neointimal proliferation induced by advanced glycation end products in a balloon injury rat model. Pharmacology. 2013;91:123-130. doi: 10.1159/000346128.
109. Telejko B, Tomasiak M, Stelmach H, Kinalska I. Platelet sodium-proton exchanger and phospholipid-dependent procoagulant activity in patients with type 2 diabetes. Metabolism. 2003;52:102-106. doi: 10.1053/ meta.2003.50016.
110. Sun YM, Su Y, Li J, Tian Y, Wang LF. Role of the Na(+)/H(+) exchanger on the development of diabetes mellitus and its chronic complications. Biochem Biophys Res Commun. 2012;427:229-231. doi: 10.1016/j.bbrc.2012.09.050.
111. Lupachyk S, Watcho P, Shevalye H, Vareniuk I, Obrosov A, Obrosova IG, Yorek MA. Na+/H+ exchanger 1 inhibition reverses manifestation of peripheral diabetic neuropathy in type 1 diabetic rats. Am J Physiol Endocrinol Metab. 2013;305:E396-E404. doi: 10.1152/ ajpendo.00186.2013.
112. Cukiernik M, Hileeto D, Downey D, Evans T, Khan ZA, Karmazyn M, Chakrabarti S. The role of the sodium hydrogen exchanger-1 in mediating diabetes-induced changes in the retina. Diabetes Metab Res Rev. 2004;20:61-71. doi: 10.1002/dmrr.421.
113. Madonna R, De Caterina R. Aquaporin-1 and sodium-hydrogen exchangers as pharmacological targets in diabetic atherosclerosis. Curr Drug Targets. 2015;16:361-365. doi: 10.2174/1389450116666141219115720.
114. Anzawa R, Seki S, Nagoshi T, Taniguchi I, Feuvray D, Yoshimura M. The role of Na+/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db/db mice. Cardiovasc Diabetol. 2012;11:33. doi: 10.1186/1475-2840-11-33.
115. Darmellah A, Baetz D, Prunier F, Tamareille S, Rücker-Martin C, Feuvray D. Enhanced activity of the myocardial Na+/H+ exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: critical role of Akt. Diabetologia. 2007;50:1335-1344. doi: 10.1007/s00125-007-0628-x.
116. Hileeto D, Cukiernik M, Mukherjee S, Evans T, Barbin Y, Downey D, Karmazyn M, Chakrabarti S. Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes Metab Res Rev. 2002;18:386-394. doi: 10.1002/dmrr.322.
117. Klisic J, Nief V, Reyes L, Ambuhl PM. Acute and chronic regulation of the renal Na/H+ exchanger NHE3 in rats with STZ-induced diabetes mellitus. Nephron Physiol. 2006;102:p27-p35. doi: 10.1159/000089091.
118. Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol. 2013;305:F1629-F1636. doi: 10.1152/ajprenal.00263.2013.
119. Li K, Su W, Li M, Chen CJ, Li YY, Lai LY, Zhang MM, Liu SJ, Fichna J, Peng A, Hao CM, Gu Y, Lin SY. Acid loading stimulates rat glomerular mesangial cells proliferation through Na(+)-H (+) exchanger isoform 1 (NHE1)-dependent pathway. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:563-569. doi: 10.1007/s00210-013-0856-1.
120. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, Stec DE. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285:17271- 17276. doi: 10.1074/jbc.R110.113175.
121. Bravo PE, Morse S, Borne DM, Aguilar EA, Reisin E. Leptin and hypertension in obesity. Vasc Health Risk Manag. 2006;2:163-169.
122. Li P, Chen GR, Wang F, Xu P, Liu LY, Yin YL, Wang SX. Inhibition of NA(+)/H(+) exchanger 1 attenuates renal dysfunction induced by advanced glycation end products in rats. J Diabetes Res. 2016;2016:1802036. doi: 10.1155/2016/1802036.
123. Schelling JR, Abu Jawdeh BG. Regulation of cell survival by Na+/H+ exchanger-1. Am J Physiol Renal Physiol. 2008;295:F625-F632. doi: 10.1152/ajprenal.90212.2008.
124. Semplicini A, Ceolotto G, Sartori M, Maresca A, Baritono E, De Toni R, Paparella I, Calò L. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide. J Nephrol. 2002;15:489-496.
125. Hryciw DH, Lee EM, Pollock CA, Poronnik P. Molecular changes in proximal tubule function in diabetes mellitus. Clin Exp Pharmacol Physiol. 2004;31:372-379. doi: 10.1111/j.1440-1681.2004.04001.x.
126. Harris RC, Homma T, Jacobson HR, Capdevila J. Epoxyeicosatrienoic acids activate Na+/H+ exchange and are mitogenic in cultured rat glomerular mesangial cells. J Cell Physiol. 1990;144:429-437. doi: 10.1002/jcp.1041440310.
127. Lupachyk S, Stavniichuk R, Komissarenko JI, Drel VR, Obrosov AA, El-Remessy AB, Pacher P, Obrosova IG. Na+/H+-exchanger-1 inhibition counteracts diabetic cataract formation and retinal oxidative-nitrative stress and apoptosis. Int J Mol Med. 2012;29:989-998. doi: 10.3892/ ijmm.2012.933.
128. Busque SM, Stange G, Wagner CA. Dysregulation of the glutamine transporter Slc38a3 (SNAT3) and ammoniagenic enzymes in obese, glucose-intolerant mice. Cell Physiol Biochem. 2014;34:575-589. doi: 10.1159/000363024.
129. Cingolani HE, Pérez NG, Cingolani OH, Ennis IL. The Anrep effect: 100 years later. Am J Physiol Heart Circ Physiol. 2013;304:H175-H182. doi: 10.1152/ajpheart.00508.2012.
130. Liu G, Hitomi H, Rahman A, Nakano D, Mori H, Masaki T, Ma H, Iwamoto T, Kobori H, Nishiyama A. High sodium augments angiotensin II-induced vascular smooth muscle cell proliferation through the ERK 1/2-dependent pathway. Hypertens Res. 2014;37:13-18. doi: 10.1038/hr.2013.108.
131. Garciarena CD, Caldiz CI, Portiansky EL, Chiappe de Cingolani GE, Ennis IL. Chronic NHE-1 blockade induces an antiapoptotic effect in the hypertrophied heart. J Appl Physiol (1985). 2009;106:1325-1331. doi: 10.1152/japplphysiol.91300.2008.
132. Leite-Moreira AF, Castro-Chaves P, Pimentel-Nunes P, Lima-Carneiro A, Guerra MS, Soares JB, Ferreira-Martins J. Angiotensin II acutely decreases myocardial stiffness: a novel AT1, PKC and Na+/H+ exchanger-mediated effect. Br J Pharmacol. 2006;147:690-697. doi: 10.1038/sj.bjp.0706659.
133. Banday AA, Siddiqui AH, Menezes MM, Hussain T. Insulin treatment enhances AT1 receptor function in OK cells. Am J Physiol Renal Physiol. 2005;288:F1213-F1219. doi: 10.1152/ajprenal.00361.2003.
134. 3 activity by angiotensin II is mediated by the activation of the angiotensin II type I receptor/phospholipase C/ calcium/calmodulin pathway in distal nephron cells. Eur J Pharmacol. 2013;721:322-331. doi: 10.1016/j.ejphar.2013.08.043.
135. Li XC, Zhuo JL. Intracellular ANG II directly induces in vitro transcription of TGF-beta1, MCP-1, and NHE-3 mRNAs in isolated rat renal cortical nuclei via activation of nuclear AT1a receptors. Am J Physiol Cell Physiol. 2008;294:C1034-C1045. doi: 10.1152/ajpcell.00432.2007.
136. Sandmann S, Yu M, Kaschina E, Blume A, Bouzinova E, Aalkjaer C, Unger T. Differential effects of angiotensin AT1 and AT2 receptors on the expression, translation and function of the Na+-H+ exchanger and Na+- HCO3- symporter in the rat heart after myocardial infarction. J Am Coll Cardiol. 2001;37:2154-2165. doi: 10.1016/S0735-1097(01)01287-6.
137. Gunasegaram S, Haworth RS, Hearse DJ, Avkiran M. Regulation of sarcolemmal Na(+)/H(+) exchanger activity by angiotensin II in adult rat ventricular myocytes: opposing actions via AT(1) versus AT(2) receptors. Circ Res. 1999;85:919-930. doi: 10.1161/01.RES.85.10.919.
138. Kemp BA, Howell NL, Keller SR, Gildea JJ, Padia SH, Carey RM. AT2 receptor activation prevents sodium retention and reduces blood pressure in angiotensin II-dependent hypertension. Circ Res. 2016;119:532-543. doi: 10.1161/CIRCRESAHA.116.308384.
139. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935. doi: 10.1172/JCI7886.
140. Pegg K, Zhang J, Pollock C, Saad S. Combined effects of PPAR γ agonists and epidermal growth factor receptor inhibitors in human proximal tubule cells. PPAR Res. 2013;2013:982462. doi: 10.1155/2013/982462.
141. Girardi AC, Knauf F, Demuth HU, Aronson PS. Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol. 2004;287:C1238-C1245. doi: 10.1152/ajpcell.00186.2004.
142. Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009;297:F1647- F1655. doi: 10.1152/ajprenal.00082.2009.
143. Farah LX, Valentini V, Pessoa TD, Malnic G, McDonough AA, Girardi AC. The physiological role of glucagon-like peptide-1 in the regulation of renal function. Am J Physiol Renal Physiol. 2016;310:F123-F127. doi: 10.1152/ajprenal.00394.2015.
144. Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM, Malnic G, Girardi AC. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol. 2011;301:F355-F363. doi: 10.1152/ajprenal.00729.2010.
145. Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G. Functional role of glucose metabolism, osmotic stress, and sodiumglucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol. 2014;25:2028-2039. doi: 10.1681/ASN.2013060588.
146. Kawase H, Bando YK, Nishimura K, Aoyama M, Monji A, Murohara T. A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis. J Mol Cell Cardiol. 2016;98:37-47. doi: 10.1016/j.yjmcc.2016.06.066.
147. von Lewinski D, Rainer PP, Gasser R, Huber MS, Khafaga M, Wilhelm B, Haas T, Mächler H, Rössl U, Pieske B. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism. 2010;59:1020-1028. doi: 10.1016/j. metabol.2009.10.025.
148. Baartscheer A, Schumacher CA, Wüst RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia. 2017;60:568-573. doi: 10.1007/s00125-016-4134-x.
149. Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Hollmann MW, Weber NC, Coronel R, Zuurbier CI. SGLT2 inhibitors inhibit NHE-1, lower [Na+]c and induced vasodilation, but only empaglilozin increases oxygen and glucose consumption in isolated mouse hearts. Presented at the American Diabetes Association meeting, San Diego, June 13, 2017.
150. Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, Dollet L, Le May C, Toumaniantz G, Manrique A, Charpentier F, Staels B, Magré J, Cariou B, Prieur X. The SGLT2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model [published online ahead of print January 4, 2017]. Diabetes. doi: 10.2337/db16-0733.
151. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15:157. doi: 10.1186/s12933-016-0473-7.
152. Vettor R, Inzucchi SE, Fioretto P. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia. 2017;60:395-398. doi: 10.1007/s00125-016-4194-y.
153. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin Ther. 2016;38:2248.e5-2264.e5. doi: 10.1016/j. clinthera.2016.08.008.
154. Sakurai S, Kuroko Y, Shimizu S, Kawada T, Akiyama T, Yamazaki T, Sugimachi M, Sano S. Effects of intravenous cariporide on release of norepinephrine and myoglobin during myocardial ischemia/reperfusion in rabbits. Life Sci. 2014;114:102-106. doi: 10.1016/j.lfs.2014.08.008.
155. Barber DL, Ganz MB. Guanine nucleotides regulate beta-adrenergic activation of Na-H exchange independently of receptor coupling to Gs. J Biol Chem. 1992;267:20607-20612.
156. Feuring M, Jester I, Tillmann HC, Bertsch T, Kugler I, Schmidt BM, Wehling M. Impact of pharmacotherapy on lymphocyte volumes and activity of the Na+/H+ exchanger in patients with congestive heart failure. Methods Find Exp Clin Pharmacol. 2001;23:409-413. doi: 10.1358/ mf.2001.23.7.662128.
157. Sonalker PA, Tofovic SP, Bastacky SI, Jackson EK. Chronic noradrenaline increases renal expression of NHE-3, NBC-1, BSC-1 and aquaporin-2. Clin Exp Pharmacol Physiol. 2008;35:594-600. doi: 10.1111/j.1440-1681.2007.04846.x.
158. Friedrich T, Burckhardt G. Inhibition of the rat renal Na+/H+ exchanger by beta-adrenergic antagonists. Biochem Biophys Res Commun. 1991;175:311-317.
159. Schäfer M, Schäfer C, Michael Piper H, Schlüter KD. Hypertrophic responsiveness of cardiomyocytes to alpha- or beta-adrenoceptor stimulation requires sodium-proton-exchanger-1 (NHE-1) activation but not cellular alkalization. Eur J Heart Fail. 2002;4:249-254. doi: 10.1016/ S1388-9842(02)00016-8.
160. Hall RA, Premont RT, Chow CW, Blitzer JT, Pitcher JA, Claing A, Stoffel RH, Barak LS, Shenolikar S, Weinman EJ, Grinstein S, Lefkowitz RJ. The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature. 1998;392:626-630. doi: 10.1038/33458.
161. Schulte EA, Hohendahl A, Stegemann H, Hirsch JR, Saleh H, Schlatter E. Natriuretic peptides and diadenosine polyphosphates modulate pH regulation of rat mesangial cells. Cell Physiol Biochem. 1999;9:310-322. doi: 16325.
162. Kilic A, Velic A, De Windt LJ, Fabritz L, Voss M, Mitko D, Zwiener M, Baba HA, van Eickels M, Schlatter E, Kuhn M. Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice. Circulation. 2005;112:2307- 2317. doi: 10.1161/CIRCULATIONAHA.105.542209.
163. Calvieri C, Rubattu S, Volpe M. Molecular mechanisms underlying effects of natriuretic peptides. J Mol Med (Berl). 2012;90:5-13.
164. Kilić A, Bubikat A, Gassner B, Baba HA, Kuhn M. Local actions of atrial natriuretic peptide counteract angiotensin II stimulated cardiac remodeling. Endocrinology. 2007;148:4162-4169. doi: 10.1210/en.2007-0182.
165. Braga-Sobrinho C, Leite-Dellova DC, Mello-Aires M. Action of ANP on the nongenomic dose-dependent biphasic effect of aldosterone on NHE1 in proximal S3 segment. J Steroid Biochem Mol Biol. 2012;128:89-97. doi: 10.1016/j.jsbmb.2011.11.011.
166. Hirsch JR, Kruhøffer M, Adermann K, Heitland A, Maronde E, Meyer M, Forssmann WG, Herter P, Plenz G, Schlatter E. Cellular localization, membrane distribution, and possible function of guanylyl cyclases A and 1 in collecting ducts of rat. Cardiovasc Res. 2001;51:553-561.
167. Ricci R, Baldini P, Bogetto L, De Vito P, Luly P, Zannetti A, Incerpi S. Dual modulation of Na/H antiport by atrial natriuretic factor in rat aortic smooth muscle cells. Am J Physiol. 1997;273(2 Pt 1):C643-C652.
168. Caramelo C, López-Farré A, Riesco A, Olivera A, Okada K, Cragoe EJ Jr, Tsai P, Briner VA, Schrier RW. Atrial natriuretic peptide and cGMP inhibit Na+/H+ antiporter in vascular smooth muscle cells in culture. Kidney Int. 1994;45:66-75. doi: 10.1038/ki.1994.8.
169. Gan XT, Gong XQ, Xue J, Haist JV, Bai D, Karmazyn M. Sodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytes. Cardiovasc Res. 2010;85:79-89. doi: 10.1093/cvr/cvp283.
170. Young M, Funder J. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology. 2003;144:3848-3851. doi: 10.1210/en.2003-0039.
171. Zhang M, Chen J, Liu S, You L, Lin S, Gu Y. The role of Na+-H+ exchanger isoform 1 in aldosterone-induced glomerulosclerosis in vivo. Ren Fail. 2009;31:726-735. doi: 10.3109/08860220903134571.
172. Zhang M, Chen J, Lai L, You L, Lin S, Hao C, Gu Y. Aldosterone promotes fibronectin synthesis in rat mesangial cells via ERK1/2-stimulated Na-H+ exchanger isoform 1. Am J Nephrol. 2010;31:75-82. doi: 10.1159/000256665.
173. Yamamuro M, Yoshimura M, Nakayama M, Abe K, Shono M, Suzuki S, Sakamoto T, Saito Y, Nakao K, Yasue H, Ogawa H. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology. 2006;147:1314-1321. doi: 10.1210/ en.2005-1244.
174. Drumm K, Kress TR, Gassner B, Krug AW, Gekle M. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell Physiol Biochem. 2006;17:21-28. doi: 10.1159/000091456.
175. Coccaro E, Mraiche F, Malo M, Vandertol-Vanier H, Bullis B, Robertson M, Fliegel L. Expression and characterization of the Na+/H+ exchanger in the mammalian myocardium. Mol Cell Biochem. 2007;302:145-155. doi: 10.1007/s11010-007-9436-3.
176. Wu MS, Biemesderfer D, Giebisch G, Aronson PS. Role of NHE3 in mediating renal brush border Na+-H+ exchange: adaptation to metabolic acidosis. J Biol Chem. 1996;271:32749-32752. doi: 10.1074/ jbc.271.51.32749.
177. Karmazyn M, Sostaric JV, Gan XT. The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure. Drugs. 2001;61:375-389.
178. Ogino K, Kinugasa Y, Kato M, Yamamoto K, Hisatome I, Anker SD, Doehner W. Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. Int J Cardiol. 2014;171:398-403. doi: 10.1016/j.ijcard.2013.12.039.
179. 1© levels in patients with chronic heart failure. Am Heart J. 2010;160:915-921. doi: 10.1016/j.ahj.2010.04.024.
180. Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T; EVALUATE Study Group. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a doubleblind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:944-953. doi: 10.1016/S2213-8587(14)70194-9.
181. Ma TK, Szeto CC. Mineralocorticoid receptor antagonist for renal protection. Ren Fail. 2012;34:810-817. doi: 10.3109/0886022X.2012.672156.
182. Schjoedt KJ, Christensen PK, Jorsal A, Boomsma F, Rossing P, Parving HH. Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. Nephrol Dial Transplant. 2009;24:3343-3349. doi: 10.1093/ ndt/gfp311.
183. Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, Shjoedt KJ, Parving HH, Rossing P. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med. 2012;29:e184- e190. doi: 10.1111/j.1464-5491.2012.03585.x.
184. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. doi: 10.1056/ NEJM199909023411001.
185. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. doi: 10.1056/NEJMoa030207.
186. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. doi: 10.1056/NEJMoa1009492.
187. Olivier A, Pitt B, Girerd N, Lamiral Z, Machu JL, McMurray JJ, Swedberg K, van Veldhuisen DJ, Collier TJ, Pocock SJ, Rossignol P, Zannad F, Pizard A. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: Insight from the EMPHASIS-HF trial [published online ahead of print March 16, 2017]. Eur J Heart Fail. doi: 10.1002/ejhf.792.
188. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392. doi: 10.1056/NEJMoa1313731.
189. Dinh Cat AN, Friederich-Persson M, White A, Touyz RM. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 2016;57:F7-F21. doi: 10.1530/JME-16-0025.
190. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526-1534. doi: 10.1093/eurheartj/ehv728.
191. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772. doi: 10.1161/ CIRCULATIONAHA.116.021887.
192. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004;24:168-175. doi: 10.1016/j.semnephrol.2003.11.001.
193. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334. doi: 10.1056/ NEJMoa1515920.
194. Persson F, Lindhardt M, Rossing P, Parving HH. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: a systematic review [published online ahead of print August 3, 2016]. J Renin Angiotensin Aldosterone Syst. doi: 10.1177/1470320316652047.
195. Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:610-621. doi: 10.1016/ S2213-8587(17)30182-1.
196. Koren W, Koldanov R, Pronin VS, Postnov IY, Peleg E, Rosenthal T, Berezin M, Postnov YV. Amiloride-sensitive Na+/H+ exchange in erythrocytes of patients with NIDDM: a prospective study. Diabetologia. 1997;40:302-306. doi: 10.1007/s001250050678.
197. Dominguez Rieg JA, de la Mora Chavez S, Rieg T. Novel developments in differentiating the role of renal and intestinal sodium hydrogen exchanger 3. Am J Physiol Regul Integr Comp Physiol. 2016;311:R1186-R1191. doi: 10.1152/ajpregu.00372.2016.
198. Avkiran M, Cook AR, Cuello F. Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach? Curr Opin Pharmacol. 2008;8:133-140. doi: 10.1016/j.coph.2007.12.007.